ÂÜÀòÂÒÂ×

Pete Roddy currently serves as a finance and accounting consultant to Second Genome and other biopharmaceutical companies. Previously, he served as SVP, Chief Accounting Officer of Cytokinetics, a biopharmaceutical company focused on impaired muscle function, from 2017 to 2019 and as a consultant since 2019. He was also Chief Financial Officer of Pain Therapeutics, which works in the neuroscience space, from 2002 to 2017. Earlier in his career, Mr. Roddy held a variety of senior management positions at a cardiovascular-focused biopharmaceutical company, COR Therapeutics, including SVP, Finance and Chief Financial Officer from 2000 and 2002. He also served as a member of the Board of Directors of Vermilion, from 2010 to 2016. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.